Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company’s web site at www.santarus.com.
- 18 years ago
QualityStocks
Santarus, Inc. (NASDAQ: SNTS)
Tags Rodman & Renshaw
Related Post
-
Mobilicom Ltd. (NASDAQ: MOB) Builds on $2.2 Million in Orders with Pipeline of Nine Tier-1 Design Wins Globally
Late last year, the Pentagon launched a $1 billion drone dominance program, with U.S. Secretary…
-
Gold Prices Rebound with Democratic Midterm Sweep In US
Disseminated on behalf of LaFleur Minerals Inc. and may include paid advertising. LaFleur Minerals Inc.…
-
Barry Ritholtz Joins Howard Lindzon to Open the Stocktoberfest 2026 Programming Day
The programming day of Stocktoberfest presented by Tradr ETFs opened on October 7 at City…